Literature DB >> 11961424

Are COPD patients with nocturnal REM sleep-related desaturations more prone to developing chronic respiratory failure requiring long-term oxygen therapy?

Margherita Sergi1, Maurizio Rizzi, Arnaldo Andreoli, Marica Pecis, Claudio Bruschi, Francesco Fanfulla.   

Abstract

BACKGROUND: Nocturnal oxygen desaturations (NOD), especially during REM sleep, have been described in patients with COPD. However, the role of NOD in the evolution of COPD to chronic respiratory failure has not been well studied.
OBJECTIVE: The aim of our study was to evaluate whether NOD is a risk factor for the development of chronic respiratory failure in COPD patients.
METHODS: We studied 34 consecutive COPD patients with a stable daytime PaO(2) >60 mm Hg over a period of 42 months. We classified patients as desaturators (NOD) when episodic desaturations were found mainly during REM sleep, independently of baseline SaO(2) values.
RESULTS: At enrollment 19 patients (55.8%) had NOD. Over the follow-up period, 10 patients (29.4%) were included in a long-term oxygen therapy (LTOT) programme (9 were desaturators). The LTOT was initiated a median time of 22 +/- 6.8 months after enrollment. Patients who were subsequently prescribed LTOT had lower values of FEV(1) at enrollment, with a higher degree of NOD and PaCO(2). Stable respiratory failure developed earlier in patients with NOD: the two enrollment curves for LTOT differed significantly (log-rank test 2.56, p = 0.005). PaCO(2), NOD and FEV(1) were statistically significantly associated, both in univariate and multivariate Cox proportional hazards analyses, with an increased risk of entering a LTOT programme.
CONCLUSIONS: We conclude that NOD may represent an independent risk factor for the development of chronic respiratory failure in COPD patients with daytime PaO(2) >60 mm Hg. A larger study is needed to confirm the role of NOD in the natural history of COPD and subsequently to identify the most appropriate therapeutic approach. Copyright 2002 S. Karger AG, Basel

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11961424     DOI: 10.1159/000056313

Source DB:  PubMed          Journal:  Respiration        ISSN: 0025-7931            Impact factor:   3.580


  4 in total

1.  The effects of sleep hypoxia on coagulant factors and hepatic inflammation in emphysematous rats.

Authors:  Jing Feng; Qing-shan Wang; Ambrose Chiang; Bao-yuan Chen
Journal:  PLoS One       Date:  2010-10-06       Impact factor: 3.240

2.  Multi-center, randomized, placebo-controlled trial of nocturnal oxygen therapy in chronic obstructive pulmonary disease: a study protocol for the INOX trial.

Authors:  Yves Lacasse; Sarah Bernard; Frédéric Sériès; Van Hung Nguyen; Jean Bourbeau; Shawn Aaron; François Maltais
Journal:  BMC Pulm Med       Date:  2017-01-09       Impact factor: 3.317

3.  Short-Term Oxygen Therapy Outcomes in COPD.

Authors:  Thibaud Soumagne; François Maltais; François Corbeil; Bruno Paradis; Marc Baltzan; Paula Simão; Araceli Abad Fernández; Richard Lecours; Sarah Bernard; Yves Lacasse
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2022-07-28

4.  A randomized trial to determine the impact of indacaterol/glycopyrronium on nighttime oxygenation and symptoms in patients with moderate-to-severe COPD: the DuoSleep study.

Authors:  Sverre Lehmann; Thomas Ringbæk; Anders Løkke; Ludger Grote; Jan Hedner; Eva Lindberg
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2019-01-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.